Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
<p>Glioblastoma (GBM) remains a cancer of high unmet clinical need. Current standard of care for GBM, consisting of maximal surgical resection, followed by ionisation radiation (IR) plus concomitant and adjuvant temozolomide (TMZ), provides less than 15-month survival benefit. Efforts by conve...
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Julkaistu: |
Frontiers Media
2023
|